Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience : Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study
Published in
ACR open rheumatology, vol. 5, no. 3, p. 149-164Publication date
2023-03First online date
2023-02-10Abstract
UNIGE affiliation entities
UNIGE research groups
Citation (ISO format)
RITCHLIN, Christopher T et al. Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience : Analysis of the Phase 3, Randomized, Placebo-Controlled DISCOVER-1 Study. In: ACR open rheumatology, 2023, vol. 5, n° 3, p. 149–164. doi: 10.1002/acr2.11523
Main files (1)
Article (Published version)
Secondary files (1)
Appendix
Identifiers
- PID : unige:176221
- DOI : 10.1002/acr2.11523
- PMID : 36762512
- PMCID : PMC10010489
